The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosisEnrico Costa, Marco Cipolli, Silvia Girotti et al.|Orphanet Journal of Rare Diseases|2022Cited by 51